RYDAPT (midostaurin)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ACUTE MYELOID LEUKEMIA WITH FMS-LIKE TYROSINE KINASE-3 (FLT3) MUTATION·+3
Novartis Pharmaceuticals
Indication
Mast cell leukemia
Mast cell leukemia is an extremely rare, highly aggressive hematologic malignancy classified as a leukemic variant of systemic mastocytosis. Read more about Mast cell leukemia
3 drugs 3 manufacturers
Drugs that treat it
Common Mast cell leukemia therapies.
AYVAKIT (avapritinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·AGGRESSIVE SYSTEMIC MASTOCYTOSIS·+3
BLUEPRINT MEDICINES
RYDAPT (midostaurin)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ACUTE MYELOID LEUKEMIA WITH FMS-LIKE TYROSINE KINASE-3 (FLT3) MUTATION·+3
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Mast cell leukemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMast cell leukemia is an extremely rare, highly aggressive hematologic malignancy classified as a leukemic variant of systemic mastocytosis.
It primarily affects the hematopoietic system, liver, spleen, peritoneum, and gastrointestinal tract, typically manifesting in adults either de novo or via secondary progression from pre-existing advanced systemic mastocytosis.
Pathophysiologically, it is defined by the fulfillment of systemic mastocytosis criteria alongside bone marrow aspirates showing at least 20% atypical, immature mast cells, frequently accompanied by multi-organ damage, cytopenias, and poor survival outcomes.
Cases are further stratified into classic (leukemic) forms, where mast cells constitute 10% or more of circulating peripheral white blood cells, and aleukemic variants with less than 10% circulating involvement.
- nih.gov
Mast cell leukemia is an extremely rare, highly aggressive hematologic malignancy classified as a leukemic variant of systemic mastocytosis Pathophysiologically, it is defined by the fulfillment of systemic mastocytosis criteria alongside bone marrow aspirates showing at least 20% atypical, immature mast cells, frequently accompanied by multi-organ damage, cytopenias, and poor survival outcomes
- cancer.gov
Mast cell leukemia is an extremely rare, highly aggressive hematologic malignancy classified as a leukemic variant of systemic mastocytosis
- nih.gov
It primarily affects the hematopoietic system, liver, spleen, peritoneum, and gastrointestinal tract, typically manifesting in adults either de novo or via secondary progression from pre-existing advanced systemic mastocytosis
- ashpublications.org
It primarily affects the hematopoietic system, liver, spleen, peritoneum, and gastrointestinal tract, typically manifesting in adults either de novo or via secondary progression from pre-existing advanced systemic mastocytosis Cases are further stratified into classic (leukemic) forms, where mast cells constitute 10% or more of circulating peripheral white blood cells, and aleukemic variants with less than 10% circulating involvement
- elsevierpure.com
It primarily affects the hematopoietic system, liver, spleen, peritoneum, and gastrointestinal tract, typically manifesting in adults either de novo or via secondary progression from pre-existing advanced systemic mastocytosis
- nih.gov
Pathophysiologically, it is defined by the fulfillment of systemic mastocytosis criteria alongside bone marrow aspirates showing at least 20% atypical, immature mast cells, frequently accompanied by multi-organ damage, cytopenias, and poor survival outcomes
- nih.gov
Pathophysiologically, it is defined by the fulfillment of systemic mastocytosis criteria alongside bone marrow aspirates showing at least 20% atypical, immature mast cells, frequently accompanied by multi-organ damage, cytopenias, and poor survival outcomes
Personalize your experience
Follow Mast cell leukemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.